Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 1
2013 1
2014 3
2015 2
2016 1
2017 2
2018 3
2019 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study.
De Ruigh A, Roman S, Chen J, Pandolfino JE, Kahrilas PJ. De Ruigh A, et al. Aliment Pharmacol Ther. 2014 Sep;40(5):531-7. doi: 10.1111/apt.12857. Epub 2014 Jul 10. Aliment Pharmacol Ther. 2014. PMID: 25041141 Free PMC article. Clinical Trial.
BACKGROUND: Recent studies have shown that Gaviscon Double Action Liquid (a combination alginate-antacid) administered post-prandially co-localises with the acid pocket, the 'reservoir' for post-prandial acid reflux. AIM: To compare the effectiveness of Ga …
BACKGROUND: Recent studies have shown that Gaviscon Double Action Liquid (a combination alginate-antacid) administered …
Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease.
Wilkinson J, Wade A, Thomas SJ, Jenner B, Hodgkinson V, Coyle C. Wilkinson J, et al. Eur J Gastroenterol Hepatol. 2019 Jan;31(1):86-93. doi: 10.1097/MEG.0000000000001258. Eur J Gastroenterol Hepatol. 2019. PMID: 30272584 Clinical Trial.
BACKGROUND: The alginate-antacid Gaviscon Double Action (Gaviscon DA) has a combined acid-neutralizing and reflux-suppressing action. ...
BACKGROUND: The alginate-antacid Gaviscon Double Action (Gaviscon DA) has a combined acid-neutralizing and reflux-suppr …
Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginate-antacid formulation (Gaviscon Double Action).
Wilkinson J, Abd-Elaziz K, den Daas I, Wemer J, van Haastert M, Hodgkinson V, Foster M, Coyle C. Wilkinson J, et al. Drug Dev Ind Pharm. 2019 Mar;45(3):430-438. doi: 10.1080/03639045.2018.1546314. Epub 2018 Dec 2. Drug Dev Ind Pharm. 2019. PMID: 30470147 Clinical Trial.
SIGNIFICANCE: Published studies have investigated the reflux-suppressing alginate component of Gaviscon Double Action (Gaviscon DA; RB, UK) but intragastric acid neutralization activity of the antacid component has not been evaluated in vivo. ...
SIGNIFICANCE: Published studies have investigated the reflux-suppressing alginate component of Gaviscon Double Action ( …
Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.
Thomas E, Wade A, Crawford G, Jenner B, Levinson N, Wilkinson J. Thomas E, et al. Aliment Pharmacol Ther. 2014 Mar;39(6):595-602. doi: 10.1111/apt.12640. Epub 2014 Jan 28. Aliment Pharmacol Ther. 2014. PMID: 24471505 Free article. Clinical Trial.
BACKGROUND: The alginate-antacid, Gaviscon Double Action (Gaviscon DA; Reckitt Benckiser, Slough, UK) suppresses reflux after meals by creating a gel-like barrier that caps and displaces the acid pocket distal to the oesophago-gastric junction. ...
BACKGROUND: The alginate-antacid, Gaviscon Double Action (Gaviscon DA; Reckitt Benckiser, Slough, UK) suppresses reflux …
Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms.
Coyle C, Crawford G, Wilkinson J, Thomas SJ, Bytzer P. Coyle C, et al. Aliment Pharmacol Ther. 2017 Jun;45(12):1524-1533. doi: 10.1111/apt.14064. Epub 2017 May 2. Aliment Pharmacol Ther. 2017. PMID: 28464343 Clinical Trial.
The nonsystemic, raft-forming action of alginates may help resolve symptoms. AIM: To assess alginate-antacid (Gaviscon Double Action, RB, Slough, UK) as add-on therapy to once-daily PPI for suppression of breakthrough reflux symptoms. ...
The nonsystemic, raft-forming action of alginates may help resolve symptoms. AIM: To assess alginate-antacid (Gaviscon Double …
Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
Sun J, Yang C, Zhao H, Zheng P, Wilkinson J, Ng B, Yuan Y. Sun J, et al. Aliment Pharmacol Ther. 2015 Oct;42(7):845-54. doi: 10.1111/apt.13334. Epub 2015 Jul 31. Aliment Pharmacol Ther. 2015. PMID: 26228097 Free PMC article. Retracted. Clinical Trial.
BACKGROUND: There is a paucity of large-scale studies evaluating the clinical benefit of the Gaviscon Double Action (DA) alginate-antacid formulation for treating gastroesophageal reflux disease (GERD) symptoms. ...
BACKGROUND: There is a paucity of large-scale studies evaluating the clinical benefit of the Gaviscon Double Action (DA …
Retraction: Randomised clinical trial: The clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China by J. Sun, C. Yang, H. Zhao, P. Zheng, J. Wilkinson, B. Ng, Y. Yuan. Aliment Pharmacol Ther. 2015;42:845-854.
[No authors listed] [No authors listed] Aliment Pharmacol Ther. 2018 Nov;48(9):1039. doi: 10.1111/apt.15018. Aliment Pharmacol Ther. 2018. PMID: 30318684 Free PMC article.
The retraction has been agreed upon following major protocol deviations at some study sites and several instances of non-compliance that are sufficiently serious to warrant the withdrawal of the Chinese New Drug Application for Gaviscon Double Action....
The retraction has been agreed upon following major protocol deviations at some study sites and several instances of non-compliance that are …
An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial 'acid pocket' in symptomatic GERD patients.
Kwiatek MA, Roman S, Fareeduddin A, Pandolfino JE, Kahrilas PJ. Kwiatek MA, et al. Aliment Pharmacol Ther. 2011 Jul;34(1):59-66. doi: 10.1111/j.1365-2036.2011.04678.x. Epub 2011 May 3. Aliment Pharmacol Ther. 2011. PMID: 21535446 Free PMC article.
Each subject was studied in three conditions: fasted, 20 min after consuming a high-fat meal and 20 min later after a 20 mL oral dose of an alginate-antacid formulation (Gaviscon Double Action Liquid, Reckitt Benckiser Healthcare, Hull, UK). ...
Each subject was studied in three conditions: fasted, 20 min after consuming a high-fat meal and 20 min later after a 20 mL oral dose of an …
A Randomized, controlled, crossover trial to investigate times to onset of the perception of soothing and cooling by over-the-counter heartburn treatments.
Strugala V, Dettmar PW, Sarratt K, Sykes J, Berry P, Thomas E. Strugala V, et al. J Int Med Res. 2010 Mar-Apr;38(2):449-57. doi: 10.1177/147323001003800208. J Int Med Res. 2010. PMID: 20515559 Free article. Clinical Trial.
The study was designed to assess the time to onset of the perceived soothing and cooling effects of the alginate raft-forming products, Gaviscon Liquid (peppermint), Gaviscon Double Action Liquid (peppermint) and Gaviscon Powder Formulation (fresh tropical), …
The study was designed to assess the time to onset of the perceived soothing and cooling effects of the alginate raft-forming products, Gavi …
16 results